Literature DB >> 12481722

Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents.

Roy B Jones1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12481722     DOI： 10.1007/978-1-4615-1173-1_15

Source DB:  PubMed          Journal:  Cancer Treat Res        ISSN： 0927-3042


× No keyword cloud information.
  8 in total

1.  Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.

Authors:  Partow Kebriaei; Timothy Madden; Reza Kazerooni; Xuemei Wang; Peter F Thall; Celina Ledesma; Yago Nieto; Elizabeth J Shpall; Chitra Hosing; Muzaffar Qazilbash; Uday Popat; Issa Khouri; Richard E Champlin; Roy B Jones; Borje S Andersson
Journal:  Biol Blood Marrow Transplant       Date:  2010-07-30       Impact factor: 5.742

2.  Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL.

Authors:  P Kebriaei; T Madden; X Wang; P F Thall; C Ledesma; M de Lima; E J Shpall; C Hosing; M Qazilbash; U Popat; A Alousi; Y Nieto; R E Champlin; R B Jones; B S Andersson
Journal:  Bone Marrow Transplant       Date:  2012-06-25       Impact factor: 5.483

3.  Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen.

Authors:  Arjen Gebraad; Roope Ohlsbom; Juho J Miettinen; Promise Emeh; Toni-Karri Pakarinen; Mikko Manninen; Antti Eskelinen; Kirsi Kuismanen; Ana Slipicevic; Fredrik Lehmann; Nina N Nupponen; Caroline A Heckman; Susanna Miettinen
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

4.  In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authors:  Dharminder Chauhan; Arghya Ray; Kristina Viktorsson; Jack Spira; Claudia Paba-Prada; Nikhil Munshi; Paul Richardson; Rolf Lewensohn; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2013-04-12       Impact factor: 12.531

5.  The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Authors:  Malin Wickström; Caroline Haglund; Henrik Lindman; Peter Nygren; Rolf Larsson; Joachim Gullbo
Journal:  Invest New Drugs       Date:  2007-10-06       Impact factor: 3.850

6.  Altered gene expression in busulfan-resistant human myeloid leukemia.

Authors:  Benigno C Valdez; David Murray; Latha Ramdas; Marcos de Lima; Roy Jones; Steven Kornblau; Daniel Betancourt; Yang Li; Richard E Champlin; Borje S Andersson
Journal:  Leuk Res       Date:  2008-03-12       Impact factor: 3.156

7.  In vitro and in vivo activity of melflufen (J1)in lymphoma.

Authors:  Maryam Delforoush; Sara Strese; Malin Wickström; Rolf Larsson; Gunilla Enblad; Joachim Gullbo
Journal:  BMC Cancer       Date:  2016-04-04       Impact factor: 4.430

Review 8.  Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.

Authors:  Fortunato Morabito; Giovanni Tripepi; Enrica Antonia Martino; Ernesto Vigna; Francesco Mendicino; Lucio Morabito; Katia Todoerti; Hamdi Al-Janazreh; Graziella D'Arrigo; Filippo Antonio Canale; Giovanna Cutrona; Antonino Neri; Massimo Martino; Massimo Gentile
Journal:  Drug Des Devel Ther       Date:  2021-07-08       Impact factor: 4.162
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.